Turnstone Biologics Revenue and Competitors

Ottawa, ON CAN



Total Funding



Estimated Revenue & Valuation

  • Turnstone Biologics's estimated annual revenue is currently $19.7M per year.(i)
  • Turnstone Biologics received $41.4M in venture funding in November 2016.
  • Turnstone Biologics's estimated revenue per employee is $155,000
  • Turnstone Biologics's total funding is $132.7M.

Employee Data

  • Turnstone Biologics has 127 Employees.(i)
  • Turnstone Biologics grew their employee count by -5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Turnstone Biologics is a privately-held immuno-oncology company dedicated to delivering breakthrough viral immunotherapies to improve survival for patients with cancer. With an experienced leadership team passionate about helping people with cancer, comprehensive capabilities in immuno-oncology discovery, basic research, translation, clinical development, manufacturing and commercialization, Turnstone Biologics is the sole company developing viral immunotherapies to drive benefit through simultaneous generation of a targeted immune response and modulation of the tumor environment. The company's engineered oncolytic Maraba virus, known as MG1, is the first therapeutic 2-in-1 approach to combine an oncolytic virus and an antigen-specific cancer vaccine. With its unprecedented dual-mechanism approach, MG1 kills cancer cells both locally and at metastatic sites throughout the body, and generates a durable immune response resulting in long-term memory to prevent recurrence. The company has developed a robust pipeline of new medicines for multiple solid tumors. The most advanced program, called Ad-MG1-MAGEA3, is being evaluated in patients with non-small cell lung cancer (NSCLC), breast cancer and esophageal cancer in two clinical trials. A second Maraba-based therapy designed for patients with human papillomavirus (HPV) positive tumors and multiple other viral immunotherapies are in development. Turnstone Biologics has entered into a research, option and license agreement with AbbVie for its next-generation viral immunotherapies. In 2017, the company was selected as a Fierce 15 winner - a designation signifying that it is considered one of the up-and-coming biotech companies expected to make big waves in the industry. Based in Ottawa, Ontario, and New York, Turnstone Biologics has raised approximately $50 million in venture capital financing since inception.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Turnstone Biologics News

2022-04-17 - Health Hires: Ichnos Sciences, Turnstone Biologics

and Turnstone Biologics Corp. have named new general counsel recently, highlighting Law360's latest roundup of personnel moves in health care...

2022-04-17 - Turnstone Biologics Announces TIL Therapy Research ...

Turnstone Biologics Corp., a clinical-stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering...

2022-04-13 - Turnstone Biologics Announces Executive Leadership ...

Turnstone Biologics Announces Executive Leadership Appointments. Additions of Venkat Ramanan, Ph.D., as Chief Financial Officer and P. Joseph...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Turnstone Biologics Funding

DateAmountRoundLead InvestorsReference
2015-10-29$UndisclosedAVersant VenturesArticle